Canaccord Genuity Reiterates a 'Buy' on Insulet (PODD); Second Partner Creates Future Opportunity
Tweet
Share
E-mailGet Alerts PODD Hot Sheet
Price: $148.16 +0.88%
Rating Summary:
22 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
22 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Insulet Corporation (NASDAQ: PODD) price target of $27.00.
Analyst, William J. Plovanic, said, "We reiterate our rating following news that Insulet has entered into a non-exclusive partnership with LifeScan (Johnson & Johnson (NYSE: JNJ)) to incorporate its OneTouch blood glucose monitoring technology into future generations of the OmniPod personal diabetes manager. While there is no immediate impact to the business or financials, we view this partnership positively as it gives PODD additional development options when it commercializes its next gen PDM."
For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.
Shares of Insulet Corporation closed at $20.02 yesterday.
Analyst, William J. Plovanic, said, "We reiterate our rating following news that Insulet has entered into a non-exclusive partnership with LifeScan (Johnson & Johnson (NYSE: JNJ)) to incorporate its OneTouch blood glucose monitoring technology into future generations of the OmniPod personal diabetes manager. While there is no immediate impact to the business or financials, we view this partnership positively as it gives PODD additional development options when it commercializes its next gen PDM."
For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.
Shares of Insulet Corporation closed at $20.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASD
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
